NASHVILLE, Tenn., Nov. 5, 2019 /PRNewswire/ -- Recovery Unplugged is proud to announce its newest treatment center Brentwood, Tennessee, jus

HOLON, ISRAEL, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preclinical results from its COM902 anti-TIGIT program supporting its potential clinic

HOLON, Israel, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preliminary results from its ongoing Phase 1 dose escalation study of COM701, a first-in-class an

BURLINGTON, Mass. and NEW YORK, Nov. 5, 2019 /PRNewswire/ -- Population health management leader Arcadia (www.arcadia.io) announced today a partnership with

Dr. Dadi Segal, Panaxia CEO: "Prof. Veit is key to our effort to successfully register our pharmaceutical cannabis for European markets" TEL-AVIV, Israel, Nov. 5, 2019 /PRNewswire/ -- Panaxia Pharmaceutical Industries, the largest manufacturer and distributor of pharmaceutical cannabis in Israel, ann

DALLAS, Nov. 5, 2019 /PRNewswire/ -- In recognition of Veterans Day, Eyemart Express, a leading national optical retailer and the fastest provider of quality eyewear, is thanking veterans,

NEENAH, Wis., Nov. 5, 2019 /PRNewswire/ -- According to recent reports from the Center of Disease Control, this cold and flu season is predicted to be a part

HOUSTON, Nov. 5, 2019 /PRNewswire/ - Fengate Asset Management ("Fengate") is pleased to announce that the firm acquired and reached financial close on the 72.6 megawatt Weaver wind project in Hancock County, Maine ("Weaver"). Fengate, on behalf of the Fengate Core Infrastructure Fund III and its affiliated entities, including an investment fund owned

REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company focused on unleashing the power of the immune system to treat cancer, today announced the upcoming presentation of preclinical data from its Immune-Stimulating Antibody Conjugate (ISAC) platform at the 34th Annual Meeting of the Society for Immun

80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months PLYMOUTH MEETING, Pa., Nov. 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today positive interim results from Inovio's Phase 2 study (NCT03491683) of newly diagnosed glioblastoma multiforme (GBM) combining Inovio'